Barclays lowered the firm’s price target on 10x Genomics to $47 from $66 and keeps an Overweight rating on the shares. The analyst previewed the Q3 earnings reports for the life science tools and diagnostics sector and dug into bioprocessing destocking and the risk of National Institutes of Health budget cuts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TXG:
- Bold NanoString investors ‘hard to find’ after injunction, says Stifel
- 10x Genomics EU win may not have clear readthrough to U.S., says Canaccord
- 10x Genomics says UPC grants preliminary injunction against NanoString
- NanoString says will ‘immediately appeal’ preliminary injunction in EU
- 10x Genomics surpasses 100 Xenium Analyzer shipments in eight months